swisspartners’s AbbVie ABBV Stock Holding History

swisspartners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,290	Closed	-$209K	–	79
2022 Q1	$209K	Buy	+1,290	New	+$187K	0.17%	75
2021 Q2	–	Sell	-2,350	Closed	-$255K	–	81
2021 Q1	$255K	Hold	2,350	–	–	0.21%	73
2020 Q4	$248K	Buy	+2,350	New	+$226K	0.22%	66

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

swisspartners's ABBV Position: Q2 2022 in Review

swisspartners sold out of AbbVie (ABBV) in Q2 2022, closing a stake of 1,290 shares — an estimated $209K sold.

swisspartners first reported a position in ABBV in Q4 2020 and held it in 3 quarters. The position peaked at $255K in Q1 2021. 3,004 funds tracked by Wall St. Rank hold ABBV as of Q2 2022.

swisspartners reported no remaining AbbVie position as of Q2 2022 after selling out during the quarter.
swisspartners sold 1,290 AbbVie shares in Q2 2022, an estimated $209K.
swisspartners first reported a position in AbbVie in Q4 2020 and held it in 3 quarters.
swisspartners's AbbVie position peaked at $255K in Q1 2021.
3,004 funds tracked by Wall St. Rank held AbbVie as of Q2 2022.

Based on swisspartners's 13F filing for Q2 2022, filed 10 Aug 2022.